Oncternal Therapeutics Revenue 2024

The Oncternal Therapeutics Revenue history

YEAR	REVENUE (undefined USD)	GROSS MARGIN (%)
2030e	332.83	4,04
2029e	233.42	5,76
2028e	0.77	1756,86
2027e	0.77	1756,86
2026e	0.77	1756,86
2025e	0.71	1882,35
2024e	1.32	1015,87
2023	0.79	1712,10
2022	1.49	902,01
2021	4.32	311,47
2020	3.38	398,22
2019	2.43	554,23
2018	-	-
2017	-	-
2016	-	-
2015	-	-
2014	-	-
2013	-	-
2012	-	-
2011	8.07	166,63
2010	56.79	23,67
2009	14.73	91,24
2008	13.53	95,20
2007	7.13	91,29
2006	7.51	89,70
2005	3.78	58,41
2004	1.87	100,00

Oncternal Therapeutics Aktienanalyse

What does Oncternal Therapeutics do?

Oncternal Therapeutics Inc is an American biotechnology company specializing in the development of cancer drugs. The company was founded in 2013 and is headquartered in San Diego, California. Oncternal Therapeutics' business model is based on identifying promising cancer drugs and advancing them through the approval process of regulatory authorities. The company utilizes both public and private funds to finance its research projects. As part of this, Oncternal Therapeutics participates in clinical trials and actively collaborates with experts in the clinical field. Over the years, the company has established several divisions to make its work more effective and efficient. One of these divisions focuses on developing molecules that activate the body's immune system against cancer cells. A prime example of this is the drug Cirmtuzumab. This antibody blocks signals that promote the growth of cancer cells while simultaneously activating the immune system to target tumor cells. Cirmtuzumab has shown positive results in the treatment of chronic lymphocytic leukemia, a form of blood cancer. Another division of Oncternal Therapeutics focuses on developing drugs that target cancer stem cells. These cells are responsible for the growth and spread of cancer cells in the body. Medications like the ROR1-targeting CAR-T preparation directly target these types of cancer cells and are intended to make cancer drugs more effective and targeted. Oncternal Therapeutics stands out from other cancer researchers in its ability to treat multiple myelomas, a cancer of the bone marrow cells, more effectively. The company has developed specific drugs that can influence the expression of specific genes in myeloma cells, thereby halting tumor growth. Key myeloma products from Oncternal Therapeutics include the TK216 and OT-82 preparations. In summary, Oncternal Therapeutics Inc is an innovative biotechnology company specializing in the development of cancer drugs. The company has a wide range of divisions, from developing drugs that activate the immune system against cancer cells to targeting cancer stem cells. The company's products show promising results in the treatment of various types of cancer and have the potential to bring about positive change for thousands of cancer patients worldwide. Oncternal Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Revenue Details

Understanding Oncternal Therapeutics's Sales Figures

The sales figures of Oncternal Therapeutics originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.

Year-to-Year Comparison

Analyzing Oncternal Therapeutics’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.

Impact on Investments

Investors often scrutinize Oncternal Therapeutics's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.

Interpreting Sales Fluctuations

Increases in Oncternal Therapeutics’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.

Frequently Asked Questions about Oncternal Therapeutics Stock

How much revenue did Oncternal Therapeutics generate this year?

Oncternal Therapeutics has achieved a revenue of 1.32 M USD this year.

How much was the turnover of the company Oncternal Therapeutics compared to the previous year?

The revenue of Oncternal Therapeutics has increased by 68.54% increased compared to the previous year.

What does revenue mean for investors?

The revenue of a company is an important indicator of its financial performance and attractiveness for investors.

Which factors influence the revenue of Oncternal Therapeutics?

The revenue of Oncternal Therapeutics is influenced by various factors, including the demand for its products and services, market conditions, and prices.

How is the revenue of Oncternal Therapeutics measured?

Revenue is typically measured in units referring to the sale of goods and services provided by the company.

How does an increase in sales affect investments?

An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.

What are the possible risks associated with a declining revenue?

A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.

Why is the sales revenue of Oncternal Therapeutics so important for investors?

The revenue of Oncternal Therapeutics is an important indicator of financial performance and attractiveness for investors.

What strategic measures can a company take to increase revenue?

A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.

How much dividend does Oncternal Therapeutics pay?

Over the past 12 months, Oncternal Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Oncternal Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Oncternal Therapeutics?

The current dividend yield of Oncternal Therapeutics is .

When does Oncternal Therapeutics pay dividends?

Oncternal Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Oncternal Therapeutics?

Oncternal Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Oncternal Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Oncternal Therapeutics located?

Oncternal Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Oncternal Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Oncternal Therapeutics from 6/6/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/6/2024.

When did Oncternal Therapeutics pay the last dividend?

The last dividend was paid out on 6/6/2024.

What was the dividend of Oncternal Therapeutics in the year 2023?

In the year 2023, Oncternal Therapeutics distributed 0 USD as dividends.

In which currency does Oncternal Therapeutics pay out the dividend?

The dividends of Oncternal Therapeutics are distributed in USD.